08/826,576 12/11/97

Set	Items	Description
S1	221956	ADJUVANT? ?
S2	522728	VACCINE? ?
S3	529488	CHOLESTEROL OR CHOLESTERYL?
S4	77040	QUATERNARY(W)AMMONIUM
S5	1248592	AMINE
S6	1203798	LIPID? ?
S7	1111	DIOLEOYLPHOSPHATIDYLETHANOLAMINE
S8	1772	DIOLEOYLPHOSPHATIDYLCHOLINE
S9	118612	LIPOSOME? ?
S10	136392	INFLUENZA
S11	85923	HEMAGGLUTININ
S12	1294192	S4 OR S5
S13	2589	S7 OR S8
S14	384	S1 AND S2 AND S3
S15	0	S S14 AND S12
S16	1064	S1 AND S2 AND S12
S17	0	S15 AND S16
S18	4	S14 AND S13
S19	3	S16 AND S13
S20	4	S18 OR S19
S21	1	S20 NOT PY>1994
S22	217	S14 AND S6
S23	286	S16 AND S6
S24	148	S22 AND S9
S25	139	S23 AND S9
S26	62	S24 NOT PY>1994
S27	75	S25 NOT PY>1994
S28	110	S26 OR S27
S29	31	S28 AND S10
S30	1103	S13 AND S9
S31	16	S30 AND S2
S32	7	S31 NOT PY>1994

?

21/3,AB/1 (Item 1 from file: 348)

00489393
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348

Liposomal compositions and processes for their production.
Liposomale Mittel sowie Verfahren zu deren Herstellung.
Compositions liposomales et leurs procedes de preparation.

PATENT ASSIGNEE:
INSTITUTO NACIONAL DE ENGENHARIA E TECNOLOGIA INDUSTRIAL, (1333511), Estrada do Paco do Lumiar, 1699 Lisboa Codex, (PT), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Meirinhos da Cruz, Maria Eugenia, Rua Maestro Raul Ferrao 43, P-1500 Lisboa, (PT)
Santana Jorge, Joao Carlos, Rua Bernardo Santareno, Lote C-22-6oC, Miratejo, P-2880 Almada, (PT)
Figueria Martins, Maria Barbara dos Anjos, Rua Luis Pedrosa de Barros, 2-2o-A., P1400 Lisboa, (PT)
Guilherme Gaspar, Maria Manuela de Jesus, Praca Dr. Ernesto Roma 8-3oA, P-1900 Lisboa, (PT)
Esteves Simoes, Aida da Conceicao, Rua da Quinta das Palmeiras, 100r/c Esq., P-2780 Oeiras, (PT)
Perez-Soler, Roman, 2904 Rice Boulevard, Houston, Texas 77005, (US)
LEGAL REPRESENTATIVE:
Powell, Stephen David et al (52311), WILLIAMS, POWELL & ASSOCIATES 34 Tavistock Street, London WC2E 7PB, (GB)
PATENT (CC, No, Kind, Date): EP 485143 A1 920513 (Basic)
APPLICATION (CC, No, Date): EP 91310180 911104;
PRIORITY (CC, No, Date): PT 95812 901106; PT 96037 901128
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-009/127; A61K-037/54;

ABSTRACT EP 485143 A1
Liposomal compositions are described containing an enzyme having L-Asparaginase activity characterized by having a protein/lipid ratio of at least 30 (mu)g/ (mu)mol, the size of liposomes being up to 1000 nm. The enzymatic activity is located in the aqueous or lipid phase or both. The compositions are prepared by forming multilamellar liposomes containing the enzyme and subjecting the liposomes to lyophilization, rehydration and extrusion under pressure.
ABSTRACT WORD COUNT: 68

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	561
SPEC A	(English)	EPABF1	5282
Total word count - document A			5843
Total word count - document B			0
Total word count - documents A + B			5843

?

29/3,AB/1 (Item 1 from file: 94)
DIALOG(R)File 94:JICST-EPlus

00358023 JICST ACCESSION NUMBER: 86A0510577 FILE SEGMENT: JICST-E
Modified vaccine. **Artificial membrane** vaccine.
NEROME KUNIAKI (1)
(1) National Inst. of Health
Kobunshi(High Polymers, Japan), 1986, VOL.35,NO.6, PAGE.563, FIG.1
JOURNAL NUMBER: F0168AAU ISSN NO: 0454-1138 CODEN: KOBUA
UNIVERSAL DECIMAL CLASSIFICATION: 615.37 577.1:576.314
LANGUAGE: Japanese COUNTRY OF PUBLICATION: Japan
DOCUMENT TYPE: Journal
ARTICLE TYPE: Commentary

29/3,AB/4 (Item 1 from file: 377)
DIALOG(R)File 377:Derwent Drug File

00525830 DERWENT ACCESSION NUMBER: 93-14984
Synthetic Immunoadjuvants: Application to Non-Specific Host Stimulation and Potentiation of Vaccine **Immunogenicity.**
Azuma I
Vaccine 10, No. 14, 1000-06, 1992

ABSTRACT:
Synthetic immunoadjuvants and their application to non-specific host stimulation and potentiation of **vaccine** immunogenicity are reviewed. N-acetylmuramyldipeptide (MDP), trehalose dimycolate (TDM, cord factor), **lipid** A (LA), chitin and related compounds are considered. The acyl-MDP analog B30-MDP as a **liposome** with **cholesterol** and **influenza** virus antigen (purified hemagglutinin-neuramidinase; B-30-virosome **vaccine**) improves survival in a mouse **influenza** model and is safe in man. B30-MDP has been used as an **adjuvant** active vehicle for experimental **vaccines** . Romurtide (RO) is synergistic with antibiotics, stimulates host resistance, induces cytokines and restores leukopenia in cancer patients. Carboxymethyl-chitin gels are possible drug/**vaccine** delivery systems (doxorubicin or zinostatin in murine tumor).

29/3,AB/5 (Item 2 from file: 377)
DIALOG(R)File 377:Derwent Drug File

00320931 DERWENT ACCESSION NUMBER: 89-13996
Enhancement of Humoral Immune Responses Against Viral Vaccines **by a non-Pyrogenic 6-O-Acyl Muramyldipeptide and Synthetic Low Toxicity Analogs of** Lipid **A.**
Tsujimoto M; Kotani S; Okunaga T; Kubo T; Takada H; Kubo T
Vaccine 7, No. 1, 39-48, 1989

ABSTRACT:
A derivative of muramyldipeptide (MDP), MDP-B30 (Daiichi), in saline, phosphate-buffered saline (PBS), squalene-PBS emulsion (s/w), Intralipid or **liposomes** stimulated antibody production in guinea pigs (s.c.) and mice (s.c. or i.p.) against **influenza vaccine** , and inactivated hepatitis B virus surface (HBs) antigen. LA-17-PP and LA-18-PP enhanced antibody responses when incorporated into **liposomes** with inactivated HBs antigen and administered to mice. Murabutide and MDP were less effective. S.c. split virus **vaccine** + B30-MDP caused injection site induration and swollen lymph nodes in guinea pigs.

29/3,AB/10 (Item 3 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00546418
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
Expression of specific immunogens using viral antigens.
Expression von spezifischen Immunogene mit Hilfe von viralen Antigenen.
Expression d'immunogenes specifiques utilisant des antigenes viraux.
PATENT ASSIGNEE:
AMERICAN HOME PRODUCTS CORPORATION, (201460), Five Giralda Farms, Madison, New Jersey 07940-0874, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)
INVENTOR:
Hung, Paul Porwen, 506 Ramblewood Drive, Bryn Mawr, Pennsylvania 19010, (US)
Lee, Shaw-Guang Lin, 155 South Spring Mill Road, Villanova, Pennsylvania 19085, (US)
Kalyan, Narender Kumar, 1587 Morgan Lane, Wayne, Pennsylvania 19087, (US)
LEGAL REPRESENTATIVE:
Connelly, Michael John et al (52262), C/o Wyeth Laboratories Huntercombe Lane South Taplow, Maidenhead Berkshire, SL6 0PH, (GB)
PATENT (CC, No, Kind, Date): EP 546787 A2 930616 (Basic)
EP 546787 A3 940601
APPLICATION (CC, No, Date): EP 92311146 921207;
PRIORITY (CC, No, Date): US 805105 911211
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: C12N-015/44; C12N-015/62; C12N-015/49; A61K-039/145; A61K-039/21; C12N-005/10; G01N-033/569;

ABSTRACT EP 546787 A2
Chimeric DNA fragments are provided which include a nucleotide sequence substantially the same as that which codes for the HA surface protein of an **influenza** A virus having five immunodominant antigenic sites, wherein a nucleotide sequence substantially the same as that which codes for a foreign epitope is inserted into the nucleotide sequence of an antigenic site. Corresponding chimeric peptides, expression vectors, and transformed hosts are provided as well. These peptides are useful in providing **vaccines** against the respective antigens and in test kits to detect the exposure to such antigens. Additionally, these peptides or their corresponding antibodies are useful in methods of treatment and prevention of the manifestations of exposure to these antigens, including immunotherapy.
ABSTRACT WORD COUNT: 118

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	423
SPEC A	(English)	EPABF1	7394
Total word count - document A			7817
Total word count - document B			0
Total word count - documents A + B			7817

29/3,AB/11 (Item 4 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00540091
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
Vaccines **and methods for their production.**
Impfstoffe und Verfahren zur Herstellung.
Vaccins et methodes de production.
PATENT ASSIGNEE:
RETROSCREEN LIMITED, (1142730), 64 Turner Street, London E1 2AD, (GB), (applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;MC;NL;PT;SE)
INVENTOR:

Oxford, John Sidney, 70 Holden Road, Woodside Park, London N12 7DY, (GB)
LEGAL REPRESENTATIVE:
Lord, Hilton David et al (59391), Marks & Clerk 57-60 Lincoln's Inn Fields, London WC2A 3LS, (GB)
PATENT (CC, No, Kind, Date): EP 514199 A2 921119 (Basic)
EP 514199 A3 931110
APPLICATION (CC, No, Date): EP 92304422 920515;
PRIORITY (CC, No, Date): GB 9110808 910517
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: A61K-039/12; A61K-039/21; A61K-039/39; C12N-007/06;

ABSTRACT EP 514199 A2
The present invention relates to the production of **vaccines** having improved safety, particularly to a process therefor which allows even an AIDS **vaccine** to be manufactured, comprising in order, the steps of:
a) treating the virus with a general inactivating agent;
b) deaggregating the virus with a suitable solvent or detergent;
c) treating the virus with an RNA and/or DNA inactivating agent; and

d) stabilising the virus with a suitable cross-linking agent.
ABSTRACT WORD COUNT: 76

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	595
SPEC A	(English)	EPABF1	6039
Total word count - document A			6634
Total word count - document B			0
Total word count - documents A + B			6634

29/3,AB/12 (Item 5 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00512136
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
Pre-S gene codes peptide hepatitis B immunogens, vaccines, **diagnostics, and synthetic** lipid **vesicle carriers.**
PreS-Gen-kodierte Peptid-Immunogene von Hepatitis B Vakzine und Diagnostika.
Immunogenes peptidiques d'hepatitis B codees par le gene pre-S, vaccins et diagnostiques.
PATENT ASSIGNEE:
New York Blood Center, Inc., (228440), 310 East 67 Street, New York, New York 10021, (US), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
CALIFORNIA INSTITUTE OF TECHNOLOGY, (294950), 1201 East California Boulevard, Pasadena California 91125, (US), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Neurath, Alexander Robert, Dr., 230 East 79 Street, New York New York 10021, (US)
Kent, Stephen B. H., Dr., 2766 Costebelle Drive, LaJolla California 92037, (US)
LEGAL REPRESENTATIVE:
Cohausz & Florack Patentanwalte (100242), Postfach 14 01 61 Schumannstrasse 97, W-4000 Dusseldorf 1, (DE)
PATENT (CC, No, Kind, Date): EP 485361 A1 920513 (Basic)
APPLICATION (CC, No, Date): EP 92100663 870425;
PRIORITY (CC, No, Date): US 856522 860428
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: C07K-013/00; G01N-033/576;

ABSTRACT EP 485361 A1

A hepatitis B **vaccine** containing a peptide with an amino acid chain of at least six consecutive amino acids within the pre-S gene coded region of the envelope of hepatitis B virus. The **vaccine** being free of an amino acid sequence corresponding to the naturally occurring envelope proteins of hepatitis B virus and a physiologically acceptable diluent. The peptide being free or linked to a carrier. The carrier being a conventional carrier or a novel carrier including a **lipid** vesicle stabilized by cross-linking and having covalently bonded active sites on the outer surface thereon. Such novel carrier being useful not only to link the novel peptide containing an amino acid chain with amino acids within the pre-S gene coded region of the surface antigen of hepatitis B virus, but can also be used to bind synthetic peptide analogues of other viral proteins, as well as bacterial, allergen and parasitic proteins of man and animals. The peptides of the invention can be utilized in diagnostics for the detection of antigens and antibodies.

ABSTRACT WORD COUNT: 173

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	275
SPEC A	(English)	EPABF1	24183
Total word count - document A			24458
Total word count - document B			0
Total word count - documents A + B			24458

29/3,AB/14 (Item 7 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

00472241

Novel muramyldipeptide derivatives and influenza vaccine **comprising the derivatives.**

Neue Muramyldipeptidderivate und Grippeimpfstoff der sie enthalt.

Nouveaux derives de muramyldipeptide et vaccin contre la grippe les contenant.

PATENT ASSIGNEE:

DAIICHI PHARMACEUTICAL CO., LTD., (215751), 14-10, Nihonbashi 3-chome, Chuo-ku, Tokyo 103, (JP), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

The Chemo-Sero-Therapeutic Research Institute, (283930), 668, Ohkubo Shimizu-machi, Kumamoto-shi Kumamoto-ken, (JP), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Oki, Masaharu, 30-10, Mihama 3-chome, Urayasu-shi, Chiba-ken, (JP)

Tsuge, Hideya, 2-3, Yokododai, Chiba-shi, Chiba-ken, (JP)

Ohkuma, Kunio, 313-20, Ohkubo, Shimizu-machi, Kumamoto-shi, Kumamoto-ken, (JP)

Oka, Tetsuya, 44-2, Koto 2-chome, Kumamoto-shi, Kumamoto-ken, (JP)

LEGAL REPRESENTATIVE:

Rost, Jurgen et al (9753), Patent- und Rechtsanwalte Bardehle-Pagenberg-Dost-Altenburg Frohwitter-Geissler & Partner Galileiplatz 1, W-8000 Munchen 80, (DE)

PATENT (CC, No, Kind, Date): EP 487909 A2 920603 (Basic)
EP 487909 A3 920812

APPLICATION (CC, No, Date): EP 91118331 911028;

PRIORITY (CC, No, Date): JP 90293335 901030; JP 90293336 901030

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C07K-009/00; A61K-039/145;

ABSTRACT EP 487909 A2

Novel muramyldipeptide derivatives such as (6-0-(2-tetradecylhexadecanoyl)-N-acetylmuramoyl)-L-alanyl-D-glutamide and (6-0-(2-tetradecylhexadecanoyl)-N-acetylmuramoyl)-L-alanyl-N

-methyl-D-glutamamide are provided. The muramyldipeptide derivatives are excellent compound as an **adjuvant** or a constituting component of virosome **vaccine** . An **influenza vaccine** comprises a complex of the muramyldipeptide derivative and an **influenza** virus antigen. The **influenza vaccine** has excellent antibody-producing capacity and safety. (see image in original document)

ABSTRACT WORD COUNT: 58

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	754
SPEC A	(English)	EPABF1	3057
Total word count - document A			3811
Total word count - document B			0
Total word count - documents A + B			3811

29/3,AB/15 (Item 8 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

00460188

ORDER fax of complete patent from KR SourceOne. See HELP ORDER348

Pre-S gene coded peptide hepatitis B immunogens, vaccines, **diagnostics, and synthetic** lipid **vesicle carriers.**

Durch pre-S-Gen kodierte Hepatitis-B-Peptid-Immunogene, Vakzine, Diagnostika und synthetische Lipid-**Blaschentrager.**

Immunogenes peptidiques d'hepatite B codes par le gene pre-S, vaccins, diagnostiques et vesicules porteurs synthetiques lipides.

PATENT ASSIGNEE:

New York Blood Center, Inc., (228440), 310 East 67 Street, New York, New York 10021, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;NL;SE)

CALIFORNIA INSTITUTE OF TECHNOLOGY, (294950), 1201 East California Boulevard, Pasadena California 91125, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;NL;SE)

INVENTOR:

Neurath, Alexander Robert, 230 East 79 Street, New York, New York 10021, (US)

Kent, Stephen B.H., 615 West California Boulevard, Pasadena, California 91105, (US)

LEGAL REPRESENTATIVE:

Cohausz & Florack Patentanwalte (100242), Postfach 14 01 61 Schumannstrasse 97, W-4000 Dusseldorf 1, (DE)

PATENT (CC, No, Kind, Date): EP 448126 A1 910925 (Basic)

APPLICATION (CC, No, Date): EP 91105948 850228;

PRIORITY (CC, No, Date): US 587090 840307; US 698499 850205

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; NL; SE

INTERNATIONAL PATENT CLASS: A61K-039/385; A61K-039/39; A61K-047/48;

ABSTRACT EP 448126 A1

A hepatitis B **vaccine** containing a peptide with an amino acid chain of at least six consecutive amino acids within the pre-S gene coded region of the envelope of hepatitis B virus. The **vaccine** being free of an amino acid sequence corresponding to the naturally occurring envelope proteins of hepatitis B virus and a physiologically acceptable diluent. The peptide being free or linked to a carrier. The carrier being a conventional carrier or a novel carrier including a **lipid** vesicle stabilized by cross-linking and having covalently bonded active sites on the outer surface thereon. Such novel carrier being useful not only to link the novel peptide containing an amino acid chain with amino acids within the pre-S gene coded region of the surface antigen of hepatitis B virus, but can also be used to bind synthetic peptide analogues of other viral proteins, as well as bacterial, allergen and parasitic proteins of man and animals. The peptides of the invention can be utilized in diagnostics for the detection of antigens and antibodies. (see image in original document)

ABSTRACT WORD COUNT: 178

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	789
SPEC A	(English)	EPABF1	19222
Total word count - document A			20011
Total word count - document B			0
Total word count - documents A + B			20011

29/3,AB/17 (Item 10 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00411415
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
MATRIX WITH IMMUNOMODULATING ACTIVITY.
MATRIZE MIT IMMUNOMODULIERENDER WIRKUNG.
MATRICE A ACTIVITE IMMUNOMODULATRICE.
PATENT ASSIGNEE:
Morein, Bror, (712050), Ollonstigen 3 Vreta, S-75590 Uppsala, (SE), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
LOVGREN, Karin, (1220060), Lindsbergsgatan 8C, S-752 40 Uppsala, (SE), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
DALSGAARD, Kristian, (1220070), Ny Vordingborgvej 80, DK-4771 Kalvehave, (DK), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
THURIN, Jan, (1220080), 28 University News, Philadelphia, PA 19104-4756, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
SUNDQUIST, Bo, (1220090), Bellmansgatan 30, S-754 28 Uppsala, (SE), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
Morein, Bror, Ollonstigen 3 Vreta, S-75590 Uppsala, (SE)
LOVGREN, Karin, Lindsbergsgatan 8C, S-752 40 Uppsala, (SE)
DALSGAARD, Kristian, Ny Vordingborgvej 80, DK-4771 Kalvehave, (DK)
THURIN, Jan, 28 University News, Philadelphia, PA 19104-4756, (US)
SUNDQUIST, Bo, Bellmansgatan 30, S-754 28 Uppsala, (SE)
LEGAL REPRESENTATIVE:
Fagerlin, Helene et al (22771), H. ALBIHNS PATENTBYRA AB P.O. Box 3137, S-103 62 Stockholm, (SE)
PATENT (CC, No, Kind, Date): EP 436620 A1 910717 (Basic)
EP 436620 B1 940810
WO 9003184 900405
APPLICATION (CC, No, Date): EP 89911115 890928; WO 89SE528 890928
PRIORITY (CC, No, Date): US 251576 880930; SE 891027 890322; SE 892780 890816
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/39; C07J-017/00; C07J-063/00;
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	270
CLAIMS B	(German)	EPBBF1	248
CLAIMS B	(French)	EPBBF1	322
SPEC B	(English)	EPBBF1	7340
Total word count - document A			0
Total word count - document B			8180
Total word count - documents A + B			8180

29/3,AB/18 (Item 11 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00375820
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348

Affinity associated vaccine.
Affinitatsassoziierter Impfstoff.
Vaccin a affinite associee.
PATENT ASSIGNEE:
THE **LIPOSOME** COMPANY, INC., (536921), One Research Way Princeton Forrestal Center, Princeton, NJ 08540, (US), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE
INVENTOR:
Popescu, Mircea C., 5 Parkway Avenue, Plainsboro, NJ 08536, (US)
Recine, Marie S., 19 Hoffman Drive, Hamilton Twp., NJ 08690, (US)
Alving, Carl L., 3 Newbold Court, Bethesda, MD 20817, (US)
Estis, Leonard F., 56 Grafton Road, Upton, MA 01568, (US)
Keyes, Lynn D., 56 Grafton Road, Upton, MA 01568, (US)
Janoff, Andrew S., 1807 South Crescent Boulevard, Yardley, PA 19067, (US)
LEGAL REPRESENTATIVE:
Martin, Jean-Jacques et al (17181), Cabinet REGIMBEAU 26, Avenue Kleber, F-75116 Paris, (FR)
PATENT (CC, No, Kind, Date): EP 356340 A1 900228 (Basic)
EP 356340 B1 941102
APPLICATION (CC, No, Date): EP 89402344 890825;
PRIORITY (CC, No, Date): US 236701 880825; US 236702 880825; US 397758 890823
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-009/50; A61K-039/145;

ABSTRACT EP 356340 A1
Disclosed is a **vaccine** against an infective agent, the **vaccine** comprising a **liposome** having an exterior and an interior and having externally disposed affinity associated antigen material of at least one, preferably nonpartitioning, antigen representative of said infective agent. Also disclosed is a method of preparation and use of this **vaccine**.
ABSTRACT WORD COUNT: 55

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPBBF1	314
CLAIMS B	(English)	EPBBF1	757
CLAIMS B	(German)	EPBBF1	721
CLAIMS B	(French)	EPBBF1	852
SPEC A	(English)	EPBBF1	5070
SPEC B	(English)	EPBBF1	5119
Total word count - document A			5384
Total word count - document B			7449
Total word count - documents A + B			12833

29/3,AB/19 (Item 12 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00334894
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
Novel polymeric immunological adjuvants.
Neue polymerische Immuno-Adjuvans.
Nouvel adjuvant **immunologique polymerique.**
PATENT ASSIGNEE:
Ribi, Hans O., (914860), 1465 Woodberry Avenue, San Mateo California 94403, (US), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Ribi, Hans O., 1465 Woodberry Avenue, San Mateo California 94403, (US)
LEGAL REPRESENTATIVE:
Glawe, Delfs, Moll & Partner Patentanwalte (100692), Postfach 26 01 62 Liebherrstrasse 20, D-8000 Munchen 26, (DE)
PATENT (CC, No, Kind, Date): EP 324455 A2 890719 (Basic)

EP 324455 A3 910327
APPLICATION (CC, No, Date): EP 89100427 890111;
PRIORITY (CC, No, Date): US 144408 880115
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/39; A61K-047/00; A61K-009/10;
ABSTRACT EP 324455 A2

Adjuvants for enhancing the immune response to an antigen are provided comprising the **adjuvant** incorporated into a **lipid** layer where the **adjuvant** is covalently or non-covalently involved in a polymeric system. Conveniently, the **adjuvant** may be conjugated to a polymerizable group and co-polymerized with a water-soluble and/or amphiphilic polymerizable monomer or combined with a polymerized amphiphile. The **adjuvant** and antigen may then be administered to a mammalian host to obtain enhanced immune response.

ABSTRACT WORD COUNT: 77

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	428
SPEC A	(English)	EPABF1	7311
Total word count - document A			7739
Total word count - document B			0
Total word count - documents A + B			7739

29/3,AB/20 (Item 13 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00334280
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
AGENT FOR PROPHYLAXIS AND TREATMENT OF VIRALLY INFECTED DISEASES.
MITTEL ZUR PROPHYLAXE UND BEHANDLUNG VON VIRALEN INFEKTIONSKRANKHEITEN.
AGENT DE PROPHYLAXIE ET DE TRAITEMENT DE MALADIES PROVOQUEES PAR DES INFECTIONS VIRALES.
PATENT ASSIGNEE:
MITSUI TOATSU CHEMICALS, Inc., (204170), 2-5 Kasumigaseki 3-chome, Chiyoda-Ku Tokyo 100, (JP), (applicant designated states: BE;CH;DE;FR;GB;IT;LI;NL;SE)
INVENTOR:
AWAYA, Akira, Dai-Ni Apartment 2-3 1541 Yabecho Totsuka-ku, Yokohama-shi Kanagawa-ken 244, (JP)
KOBAYASHI, Hisashi, Miyanodai Apartment No. 46 2141, Togo, Mobara-shi Chiba-ken 297, (JP)
ISHIZUKA, Yusaku, 21, Honmokuosatocho Naka-ku, Yokohama-shi Kanagawa-ken 231, (JP)
ABE, Hayao, Miyanodai Apartment No. 16 2141, Togo, Mobara-shi Chiba-ken 297, (JP)
LEGAL REPRESENTATIVE:
VOSSIUS & PARTNER (100311), Postfach 86 07 67, D-81634 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 343258 A1 891129 (Basic)
EP 343258 A1 900530
EP 343258 B1 930901
WO 8904667 890601
APPLICATION (CC, No, Date): EP 88910111 881124; WO 88JP1183 881124
PRIORITY (CC, No, Date): JP 87294200 871124
DESIGNATED STATES: BE; CH; DE; FR; GB; IT; LI; NL; SE
INTERNATIONAL PATENT CLASS: A61K-037/43; C07K-007/06
LANGUAGE (Publication,Procedural,Application): English; English; Japanese
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	264
CLAIMS B	(German)	EPBBF1	191
CLAIMS B	(French)	EPBBF1	320
SPEC B	(English)	EPBBF1	5104
Total word count - document A			0

Total word count - document B 5879
Total word count - documents A + B 5879

29/3,AB/21 (Item 14 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 1997 EUROPEAN PATENT OFFICE. All rts. reserv.

00332137
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
VACCINATION AGAINST RABIES-RELATED VIRUSES.
IMPFEN GEGEN MIT DER TOLLWUT VERWANDTE VIREN.
VACCINATION CONTRE DES VIRUS APPARENTES A LA RAGE.
PATENT ASSIGNEE:
THE WISTAR INSTITUTE, (319701), Thirty-Sixth Street at Spruce, Philadelphia Pennsylvania 19104-4268, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
DIETZSCHOLD, Bernhard, 3034 Goshen Road, Newton Square, PA 19073, (US)
KOPROWSKI, Hilary, 334 Fairhill Road, Wyneewood, PA 19096, (US)
LEGAL REPRESENTATIVE:
Dean, John Paul et al (72771), Withers & Rogers 4 Dyer's Buildings Holborn, London EC1N 2JT, (GB)
PATENT (CC, No, Kind, Date): EP 326598 A1 890809 (Basic)
WO 8900861 890209
APPLICATION (CC, No, Date): EP 88906760 880729; WO 88US2529 880729
PRIORITY (CC, No, Date): US 79639 870730
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/205; C07K-007/10;

ABSTRACT EP 326598 A1
Methods of vaccinating to induce protective immunity to rabies and rabies-related viruses are taught wherein certain synthetic, genetically engineered, or rabies-derived polypeptides are used. The sequence of the polypeptides is derived from the N protein. Both B and T cells are stimulated by these antigenic polypeptides to provide immunity to rabies and other related infections.
ABSTRACT WORD COUNT: 59

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	390
SPEC A	(English)	EPABF1	3857
Total word count - document A			4247
Total word count - document B			0
Total word count - documents A + B			4247

29/3,AB/24 (Item 17 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 1997 EUROPEAN PATENT OFFICE. All rts. reserv.

00312043
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
Vaccine **for generating an immunogenic T cell response protective against rabies virus.**
Impfstoff zur Erzeugung einer gegen Tollwutvirus schutzenden immunogenen T-Zellen-Respons.
Vaccin pour provoquer une reponse immunogene des cellules-T protectrice contre le virus de la rage.
PATENT ASSIGNEE:
THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, (322060), 36th & Spruce Streets, Philadelpia, PA 19104, (US), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Heber-Katz, Ellen, 2300 Walnut Street, Philadelphia Pennsylvania 19103,

(US)
Dietzschold, Bernhard, 3430 Goshen Road, Newton Square Pennsylvania 19073
, (US)
LEGAL REPRESENTATIVE:
Hale, Stephen Geoffrey et al (31411), J.Y. & G.W. Johnson Furnival House
14/18 High Holborn, London WC1V 6DE, (GB)
PATENT (CC, No, Kind, Date): EP 290246 A2 881109 (Basic)
EP 290246 A3 900131
APPLICATION (CC, No, Date): EP 88304045 880505;
PRIORITY (CC, No, Date): US 47443 870508
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/205; C07K-007/00; A61K-037/02;
A61K-039/385;

ABSTRACT EP 290246 A2
Vaccines which generate an immunogenic T cell response protective against a rabies virus disease state, comprise an immunologically effective amount of (1) a peptide-fatty acid conjugate, (2) a **liposome** composition and (3) an **adjuvant** . The conjugate (1) has the formula (see image in original document) where R(min) and R are alkyl groups containing 5 to 30 carbon atoms, and R(''') is selected from the group consisting of hydrogen and at least one amino acid residue, and X is an amino acid sequence corresponding to that of a peptide fragment derived from a protein of the virus which produces a T cell response, or a synthetic replica of said fragment.
ABSTRACT WORD COUNT: 114

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	483
SPEC A	(English)	EPABF1	11049
Total word count - document A			11532
Total word count - document B			0
Total word count - documents A + B			11532

29/3,AB/25 (Item 18 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00282597
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
VACCINE **AND METHOD OF PREPARATION.**
IMPFSTOFF UND VERFAHREN ZUR HERSTELLUNG.
VACCIN ET PROCEDE DE PREPARATION.
PATENT ASSIGNEE:
EMORY UNIVERSITY, (382080), 1380 South Oxford Road, Atlanta, GA 30322,
(US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
HUNTER, Robert, L., 3640 Churchwell Court, Tucker, GA 30084, (US)
LEGAL REPRESENTATIVE:
Sternagel, Hans-Gunther, Dr. et al (46851), Patentanwalte Dr. Michael
Hann Dr. H.-G. Sternagel Sander Aue 30, D-51465 Bergisch Gladbach, (DE)
PATENT (CC, No, Kind, Date): EP 283505 A1 880928 (Basic)
EP 283505 A1 891227
EP 283505 B1 940706
WO 8801873 880324
APPLICATION (CC, No, Date): EP 87906496 870819; WO 87US2056 870819
PRIORITY (CC, No, Date): US 909964 860922; US 75187 870716
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/02; A61K-039/12; A61K-039/295;
A61K-039/385;
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	824

CLAIMS B	(German)	EPBBF1	798
CLAIMS B	(French)	EPBBF1	849
SPEC B	(English)	EPBBF1	5734

Total word count - document A 0
Total word count - document B 8205
Total word count - documents A + B 8205

29/3,AB/27 (Item 20 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

00267173
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
New oligosaccharides, immunogens and vaccines, **and methods for preparing such oligosaccharides, immunogens and** vaccines.
Oligosaccharide, Immunogene und Impstoffe und Verfahren zur Herstellung dieser Oligosaccharide, Immunogene und Impstoffe.
Oligosaccharides, immunogenes et vaccins et procede pour la preparation de ces oligosaccharides, immunogenes et vaccins.

PATENT ASSIGNEE:
De Staat der Nederlanden, represented by the Deputy Director-General of the RIVM of Bilthoven, (935230), Antonie van Leeuwenhoeklaan 9, NL-3720 BA Bilthoven, (NL), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Beuvery, Eduard Coen, Kerkstraat 66, NL-4132 AG Vianen, (NL)
Evenberg, Adolf, Vaartserijnstraat 104, NL-3523 TE Utrecht, (NL)
Poolman, Jan Theunis, Leeteinde 8, NL-1151 Broek In Waterland, (NL)
Van Boom, Jacobus Hubertus, Het Wedde 107, NL-2253 AD Voorschoten, (NL)
Hoogerhout, Peter, Idenburgstraat 13, NL-2805 SZ Gouda, (NL)
Van Boeckel, Constant Adriaan Anton, Mercuriusstraat 32, NL-5345 LX Oss, (NL)
LEGAL REPRESENTATIVE:
Hermans, Franciscus G.M. (20111), Patent Department AKZO N.V. Pharma Division P.O. Box 20, NL-5340 BH Oss, (NL)
PATENT (CC, No, Kind, Date): EP 276516 A2 880803 (Basic)
EP 276516 A3 880817
EP 276516 B1 930317
APPLICATION (CC, No, Date): EP 87202625 871228;
PRIORITY (CC, No, Date): NL 863325 861231
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: C07H-015/04; A61K-039/102;

ABSTRACT EP 276516 A2
The invention relates to new oligosaccharides comprising the structure (D-ribose-D-ribitol-phosphate)(sub(m)), (D-ribitol-phosphate-D-ribose)(sub(m)) or (phosphate-D-ribose-D-ribitol)(sub(m)), m being 2,3,4 .... 19 or 20, to immunogens containing such oligosaccharide, to **vaccines** containing such immunogens and to methods for preparing such oligosaccharides, immunogens and **vaccines** . The **vaccine** is very suitable for treating infections caused by Haemophilus Influenzae type b.

ABSTRACT WORD COUNT: 61
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	505
CLAIMS B	(German)	EPBBF1	1039
CLAIMS B	(French)	EPBBF1	1097
SPEC B	(English)	EPBBF1	10408

Total word count - document A 0
Total word count - document B 13049
Total word count - documents A + B 13049

29/3,AB/30 (Item 23 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

00216561
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
Vaccine **for generating an immunogenic T cell response protective against a virus.**
Impfstoff fur die Erzeugung einer gegen ein Virus schutzenden immunogenen T-Zellen-Antwort.
Vaccin produisant une reponse en cellules T immunogenes protectrice contre un virus.
PATENT ASSIGNEE:
THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, (322060), 36th & Spruce Streets, Philadelpia, PA 19104, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
Heber-Katz, Ellen, 2300 Walnut Street, Philadelphia Pennsylvania 19103, (US)
Dietzschold, Bernhard, 3430 Goshen Road, Newton Square, Pennsylvania 19073, (US)
LEGAL REPRESENTATIVE:
Newby, John Ross et al (34311), J.Y. & G.W. Johnson Furnival House 14/18 High Holborn, London WC1V 6DE, (GB)
PATENT (CC, No, Kind, Date): EP 203676 A2 861203 (Basic)
EP 203676 A3 880302
EP 203676 B1 920129
APPLICATION (CC, No, Date): EP 86301223 860220;
PRIORITY (CC, No, Date): US 725087 850419
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/12; A61K-037/02; A61K-039/245; A61K-039/385; C07K-017/00;

ABSTRACT EP 203676 A2
Vaccine for generating an immunogenic T cell response protective against a virus.
A **vaccine** for generating an immunogenic T cell response protective against a virus, such as a herpes virus, comprising an immunologically effective amount of (1) a peptide-fatty acid conjugate, the peptide having an amino acid sequence corresponding to the sequence of a fragment of a glycoprotein of the virus which produces a T cell response, or a synthetic replica of such fragment, (2) a **liposome** composition comprising a mixture of phosphatidyl choline, **cholesterol** and lysophosphatidyl choline, and (3) complete Freund's **adjuvant** .
ABSTRACT WORD COUNT: 95

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	1557
CLAIMS B	(German)	EPBBF1	1422
CLAIMS B	(French)	EPBBF1	1736
SPEC B	(English)	EPBBF1	3054
Total word count - document A			0
Total word count - document B			7769
Total word count - documents A + B			7769

29/3,AB/31 (Item 24 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00189516
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines **and reagents.**
Immunogenischer Komplex, Verfahren zu seiner Herstellung und Verwendung desselben als Immunostimulans, Impfstoffe und Reagenzien.

Complexe immunogenique, procede de preparation et son utilisation comme immunostimulant, vaccins et reactifs.

PATENT ASSIGNEE:
Morein, Bror, (712050), Ollonstigen 3 Vreta, S-75590 Uppsala, (SE),
(applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
Morein, Bror, Ollonstigen 3 Vreta, S-75590 Uppsala, (SE)
LEGAL REPRESENTATIVE:
Fagerlin, Helene et al (22771), H. ALBIHNS PATENTBYRA AB P.O. Box 3137, S-103 62 Stockholm, (SE)

PATENT (CC, No, Kind, Date): EP 180564 A2 860507 (Basic)
EP 180564 A3 880601
EP 180564 B1 910717
APPLICATION (CC, No, Date): EP 85850326 851016;
PRIORITY (CC, No, Date): SE 845493 841101
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/385; A61K-039/44; A61K-039/39; A61K-045/05;

ABSTRACT EP 180564 A2

Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, **vaccines** and reagents.

The invention relates to a process for preparing an immunogenic complex comprising a carrier molecule prepared by mixing viruses, mycoplasmas, bacterias, animal cells or proteins or peptides having hydrophobic regions with one or more solubilizing agents, whereby a complex having been formed between proteins or peptides and solubilizing agents, whereafter the proteins or the peptides have been separated from the solubilizing agent in the presence of a glycoside solution which contains one or more glycosides having hydrophobic and hydrophilic regions in a concentration of at least the critical micellular concentration, or alternatively have been separated from the solubilizing agent and transferred directly to the aforementioned glycoside solution, and the carrier molecule being bound to one or more molecules selected from peptides, proteins, carbohydrates, lipoproteins, glycolipides or small molecules, such as biotine, by coupling with known methods between functional coupling groups in the bound molecules and functional groups in the peptides or the proteins in the carrier molecule.

The invention also relates to a method for preparing such immunogenic complexes, compositions, **vaccines** containing such complexes and to reagents.

ABSTRACT WORD COUNT: 198

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	2040
CLAIMS B	(German)	EPBBF1	1976
CLAIMS B	(French)	EPBBF1	2409
SPEC B	(English)	EPBBF1	14046
Total word count - document A			0
Total word count - document B			20471
Total word count - documents A + B			20471

?

32/3,AB/1 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

9166038 EMBASE No: 94108085
Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes
Philip R.; Brunette E.; Kilinski L.; Murugesh D.; McNally M.A.; Ucar K.; Rosenblatt J.; Okarma T.B.; Lebkowski J.S.
Applied Immune Sciences, Inc., 5301 Patrick Henry Dr., Santa Clara, CA 95054 USA
MOL. CELL. BIOL. (USA) , 1994, 14/4 (2411-2418) CODEN: MCEBD ISSN: 0270-7306
LANGUAGES: English SUMMARY LANGUAGES: English
We have used cationic **liposomes** to facilitate adeno-associated virus (AAV) plasmid transfections of primary and cultured cell types. AAV plasmid DNA complexed with **liposomes** showed levels of expression several fold higher than those of complexes with standard plasmids. In addition, long-term expression (>30 days) of the gene, unlike the transient expression demonstrated by typical **liposome** -mediated transfection with standard plasmids, was observed. Southern analysis of chromosomal DNA further substantiated the hypothesis that the long-term expression was due to the presence of the transgene in the AAV plasmid-transfected group and not in the standard plasmid-transfected group. AAV plasmid-**liposome** complexes induced levels of transgene expression comparable to those obtained by recombinant AAV transduction. Primary breast, ovarian, and lung tumor cells were transfectable with the AAV plasmid DNA- **liposome** complexes. Transfected primary and cultured tumor cells were able to express transgene product even after lethal irradiation. High-level gene expression was also observed in freshly isolated CD3+, CD4+, and CD8+ T cells from normal human peripheral blood. Transfection efficiency ranged from 10 to 50% as assessed by intracellular interleukin-2 levels in interleukin- 2-transfected cells. The ability to express transgenes in primary tumor and lymphoid cells may be applied toward tumor **vaccine** studies and protocols which may eventually permit highly specific modulation of the cellular immune response in cancer and AIDS.

32/3,AB/2 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

6319880 EMBASE No: 87056533
Biodistribution of pH-sensitive immunoliposomes
Connor J.; Norley N.; Huang L.
Department of Biochemistry, University of Tennessee, Knoxville, TN 37996-0840 USA
BIOCHIM. BIOPHYS. ACTA (NETHERLANDS) , 1986, 884/3 (474-481) CODEN: BBGSB
SERIES: SER. GEN. SUBJ.
LANGUAGES: ENGLISH
Liposomes composed of either **dioleoylphosphatidylethanolamine** and oleic acid (pH-sensitive) or **dioleoylphosphatidylcholine** and oleic acid pH-insensitive) were injected into C3H/Balb/c mice in order to determine the tissue distribution of both the lipid and the aqueous content. The lipid component was monitored by use of (sup 3H)cholestanyl ether and the aqueous content was monitored by use of encapsulated sup 1sup 2sup 5I-tyraminyl-inulin. The pH-insensitive **liposomes** injected into both types of mice were rapidly cleared from the blood stream followed by accumulation primarily in the liver, followed by the spleen. The presence of a monoclonal antibody on the **liposome** surface caused a slight acceleration in liver accumulation, though generally gave the same profile as the antibody-free **liposomes** . pH-sensitive **liposomes** were leaky upon exposure to the mouse plasma following injection. The lipid component, though, displayed a large amount (e.g., 50-70% in C3H mice) of accumulation in the lung for up to 6 h, followed by a subsequent appearance in the liver

and spleen. The presence of monoclonal antibody has no effect on the tissue distribution profile. These results indicate that the pH-sensitive **liposomes** , although ineffective as an aqueous drug delivery agent, may be effective as a means of delivering lipophilic drugs to the lung.

32/3,AB/3 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

6263515 EMBASE No: 87000140
Target-sensitive immunoliposomes: Preparation and characterization
Ho R.J.Y.; Rouse B.T.; Huang L.
Department of Biochemistry, University of Tennessee, Knoxville, TN 37996-0840 USA
BIOCHEMISTRY (USA) , 1986, 25/19 (5500-5506) CODEN: BICHA
LANGUAGES: ENGLISH
A novel target-sensitive immunoliposome was prepared and characterized. In this design, target-specific binding of antibody-coated **liposomes** was sufficient to induce bilayer destabilization, resulting in a site-specific release of **liposome** contents. Unilamellar **liposomes** were prepared by using a small quantity of palmitoyl-immunoglobulin G (pIgG) to stabilize the bilayer phase of the unsaturated **dioleoylphosphatidylethanolamine** (PE) which by itself does not form stable **liposomes** . A mouse monoclonal IgG antibody to the glycoprotein D of Herpes simplex virus (HSV) and PE were used in this study. A minimal coupling stoichiometry of 2.2 palmitic acids per IgG was essential for the stabilization activity of pIgG. In addition, the minimal pIgG to PE molar ratio for stable **liposomes** was 2.5 x 10sup -sup 4. PE immunoliposomes bound with HSV-infected mouse L929 cells with an apparent K(d) of 1.00 x 10sup -sup 8 M which was approximately the same as that of the native antibody. When 50 mM calcein was encapsulated in the PE immunoliposomes as an aqueous marker, binding of the **liposomes** to HSV-infected cells resulted in a cell concentration dependent lysis of the **liposomes** as detected by the release of the encapsulated calcein. Neither uninfected nor Sendai virus infected cells caused a significant amount of calcein release. Therefore, the release of calcein from PE immunoliposomes was target specific. **Dioleoylphosphatidylcholine** immunoliposomes were not lysed upon contact with infected cells under the same conditions, indicating that PE was essential for the target-specific **liposome** destabilization. Since 70% of palmitic acid was located on the Fc portion of the pIgG molecule, pIgG was proposed to stabilize the PE **liposomes** by inserting either the acylated Fc portion of the Fc-linked palmitic acid into the lipid bilayer and leaving the Fab portion available at the surface for antigen binding. Destabilization of the **liposomes** upon binding with a multivalent antigen may involve a local aggregation of pIgG at the contact area (contact capping). These **liposomes** may be useful for site-specific drug delivery and **liposome** -based immunoassays.

32/3,AB/4 (Item 1 from file: 434)
DIALOG(R)File 434:Scisearch(R) Cited Ref Sci

12751047 Genuine Article#: MM262 Number of References: 43
Title: MEMBRANE FUSION-INHIBITING PEPTIDES DO NOT INHIBIT INFLUENZA-VIRUS FUSION OR THE CA2+-INDUCED FUSION OF NEGATIVELY CHARGED VESICLES
Author(s): STEGMANN T
Corporate Source: UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70/CH-4056 BASEL//SWITZERLAND/
Journal: JOURNAL OF BIOLOGICAL CHEMISTRY, 1993, V268, N36 (DEC 25), P 26886-26892
ISSN: 0021-9258
Language: ENGLISH Document Type: ARTICLE
Abstract: Short hydrophobic N-carbobenzoxy oligopeptides are known to inhibit the infectivity of several enveloped viruses. Recently, it was shown that they inhibited the fusion of Sendai virus with N-methyl-**dioleoylphosphatidylethanolamine** (N-methyl-DOPE) **liposomes** as well

as the low pH-induced fusion of these **liposomes** with each other (Kelsey, D. R., Flanagan, T. D., Young, J. E., and Yeagle, P. L. (1990) J. Biol. Chem. 265, 12178-12183). Therefore it was concluded that the peptides inhibit membrane fusion, an important step in viral infectivity. Here, it is shown that this peptide and a series of similar peptides did not inhibit influenza virus fusion with N-methyl-DOPE or other **liposomes** . In fact, some peptides enhanced the overall rate of fusion of influenza virus with N-methyl-DOPE **liposomes** . In our hands, the peptides did not inhibit influenza infectivity in Madin-Darby canine kidney cells or influenza-induced hemolysis either. They also did not inhibit the Ca2+-induced fusion between cardiolipin or phosphatidylserine **liposomes** . However, the inhibitory effect of one of the peptides on the fusion of Sendai virus with N-methyl-DOPE **liposomes** and on N-methyl-DOPE **liposome** -**liposome** fusion could be reproduced. These data indicate that the peptides do not, as had been suggested (Yeagle, P. L., Young, J. E., Hui, S. W., and Epand, R. M. (1992) Biochemistry 31, 3177-3183), act by preventing the formation of lipid structures with small radii of curvature, such as the inverted phase intermediates that are thought to be involved in N-methyl-DOPE fusion. The results also suggest that the mechanism of inhibition of Sendai virus infection and N-methyl-DOPE fusion by the peptides may be different after all.

32/3,AB/5 (Item 2 from file: 434)
DIALOG(R)File 434:Scisearch(R) Cited Ref Sci

11597279 Genuine Article#: HW136 Number of References: 38
Title: PROCESSING OF EXOGENOUS LIPOSOME-**ENCAPSULATED ANTIGENS INVIVO GENERATES CLASS-I MHC-RESTRICTED T-CELL RESPONSES**
Author(s): COLLINS DS; FINDLAY K; HARDING CV
Corporate Source: WASHINGTON UNIV,SCH MED,DEPT PATHOL,660 S EUCLID AVE/ST LOUIS//MO/63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,660 S EUCLID AVE/ST LOUIS//MO/63110
Journal: JOURNAL OF IMMUNOLOGY, 1992, V148, N11 (JUN 1), P3336-3341
Language: ENGLISH Document Type: ARTICLE
Abstract: Acid-sensitive **liposomes** have been developed for cytosolic delivery of encapsulated substances. We now demonstrate delivery of **liposome** -encapsulated Ag into the class I MHC Ag processing pathway in peritoneal macrophages in vitro using several types of acid-sensitive **liposomes** , including those composed of **dioleoylphosphatidylethanolamine** (DOPE)/palmitoylhomocysteine, DOPE/cholesterol hemisuccinate, DOPE/dioleoylsuccinylglycerol, and DOPE/dipalmitoylsuccinylglycerol. Our previous studies showed that acid-resistant **liposomes** (**dioleoylphosphatidylcholine** /dioleoylphosphatidylserine) did not engender class I-mediated presentation in vitro. However, in vivo immunization with OVA encapsulated in acid-resistant as well as acid-sensitive **liposomes** generated class I MHC-restricted T cell responses, as determined by subsequent in vitro cytotoxicity assays using OVA-transfected target cells. Target lysis by these cells was OVA- and class I MHC (K(b))-specific. This response was not generated by immunization with equivalent amounts of soluble OVA. Thus, a pathway for in vivo class I processing of Ag encapsulated in acid-resistant **liposomes** has been missed in vitro, perhaps because it is dependent on specific populations of APC or interactions between cells that have not been reconstituted in vitro. This pathway may explain the ability of many exogenous particulate Ag (**liposomes** , bacteria, parasites, and mammalian cells) to generate class I MHC-restricted T cell responses.

32/3,AB/6 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00489393

ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
Liposomal compositions and processes for their production.
Liposomale Mittel sowie Verfahren zu deren Herstellung.
Compositions liposomales et leurs procedes de preparation.
PATENT ASSIGNEE:
INSTITUTO NACIONAL DE ENGENHARIA E TECNOLOGIA INDUSTRIAL, (1333511), Estrada do Paco do Lumiar, 1699 Lisboa Codex, (PT), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Meirinhos da Cruz, Maria Eugenia, Rua Maestro Raul Ferrao 43, P-1500 Lisboa, (PT)
Santana Jorge, Joao Carlos, Rua Bernardo Santareno, Lote C-22-6oC, Miratejo, P-2880 Almada, (PT)
Figueria Martins, Maria Barbara dos Anjos, Rua Luis Pedrosa de Barros, 2-2o-A., P1400 Lisboa, (PT)
Guilherme Gaspar, Maria Manuela de Jesus, Praca Dr. Ernesto Roma 8-3oA, P-1900 Lisboa, (PT)
Esteves Simoes, Aida da Conceicao, Rua da Quinta das Palmeiras, 100r/c Esq., P-2780 Oeiras, (PT)
Perez-Soler, Roman, 2904 Rice Boulevard, Houston, Texas 77005, (US)
LEGAL REPRESENTATIVE:
Powell, Stephen David et al (52311), WILLIAMS, POWELL & ASSOCIATES 34 Tavistock Street, London WC2E 7PB, (GB)
PATENT (CC, No, Kind, Date): EP 485143 A1 920513 (Basic)
APPLICATION (CC, No, Date): EP 91310180 911104;
PRIORITY (CC, No, Date): PT 95812 901106; PT 96037 901128
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-009/127; A61K-037/54;

ABSTRACT EP 485143 A1
Liposomal compositions are described containing an enzyme having L-Asparaginase activity characterized by having a protein/lipid ratio of at least 30 (mu)g/ (mu)mol, the size of **liposomes** being up to 1000 nm. The enzymatic activity is located in the aqueous or lipid phase or both. The compositions are prepared by forming multilamellar **liposomes** containing the enzyme and subjecting the **liposomes** to lyophilization, rehydration and extrusion under pressure.
ABSTRACT WORD COUNT: 68

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	561
SPEC A	(English)	EPABF1	5282
Total word count - document A			5843
Total word count - document B			0
Total word count - documents A + B			5843

32/3,AB/7 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00334155
ORDER fax of complete patent from KR SourceOne. See HELP ORDER348
POLYENE MACROLIDE PRE-LIPOSOMAL POWDERS.
POLYENMAKROLIDE ENTHALTENDE PROLIPOSOMALE PULVER.
POUDRES PRE-LIPOSOMIQUES DE MACROLIDE DE POLYENE.
PATENT ASSIGNEE:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, (991090), 201 West 7th Street, Austin, TX 78701, (US), (applicant designated states: AT;BE;DE;FR;GB;IT;LU;NL;SE)
INVENTOR:
MEHTA, Reeta, 8711 Ilona Lane A, Houston, TX 77000, (US)
LOPEZ-BERESTEIN, Gabriel, 5630 Rutherglenn, Houston, TX 77000, (US)
LEGAL REPRESENTATIVE:
Dost, Wolfgang, Dr.rer.nat.,Dipl.-Chem. et al (3042), Patent- &

Rechtsanwalte Bardehle . Pagenberg . Dost . Altenburg . Frohwitter . Geissler & Partner Galileiplatz 1 Postfach 86 06 20, W-8000 Munchen 86, (DE)

PATENT (CC, No, Kind, Date): EP 380584 A1 900808 (Basic)
EP 380584 B1 920318
WO 8903208 890420

APPLICATION (CC, No, Date): EP 88909920 881017; WO 88US3652 881017

PRIORITY (CC, No, Date): US 109813 871016

DESIGNATED STATES: AT; BE; DE; FR; GB; IT; LU; NL; SE

INTERNATIONAL PATENT CLASS: A61K-009/50; A61K-031/71;

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	460
CLAIMS B	(German)	EPBBF1	469
CLAIMS B	(French)	EPBBF1	546
SPEC B	(English)	EPBBF1	3335
Total word count - document A			0
Total word count - document B			4810
Total word count - documents A + B			4810

?